|ACCELERATING MEDICINES PARTNERSHIP (AMP)|
|New Resources Announcements|
|Written by Carmen Bou-Crick|
|Tuesday, 18 February 2014 00:00|
Dr. Frances Collins, NIH Director, recently announced the launching of the Accelerating Medicines Partnership (AMP) which will “strive to identify better targets so we can develop better drugs at a faster pace.” Participants include the NIH, Foundation for the NIH, 10 biopharmaceutical firms (AbbVie, Biogen Idec, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Lilly, Merck, Pfizer, Sanofi, Takeda) and several non-profit organizations and patient-advocacy groups (Alzheimer’s Association, American Diabetes Association, Lupus Foundation of America, Foundation for the NIH, Geoffrey Beene Foundation, PhRMA, Rheumatology Research Foundation, USAgainstAlzheimer’s).
The AMP will begin by investing $230 million in pilot projects in three disease areas:
• Alzheimer’s disease
To read more about AMP, please visit the website at: http://www.nih.gov/science/amp/index.htm